ChinaDaily Briefs

China: Greatview Aseptic Packaging, CNOOC Ltd, 21Vianet Group, Zhihu Technology, Tencent, China Conch Venture Holdings, Asymchem Laboratories, Sino Ocean Land and more

In today’s briefing:

  • Greatview (468 HK): A Packing Case Pick
  • CNOOC RMB Share Prices at Small Premium (But CNOOC Still Cheap To Peers)
  • VNET’s Languishing Shares Draws an Opportunistic $8.00 Bid
  • Zhihu HK Secondary – Going Further than Autohome and Weibo, Stock Might Go Further Down as Well
  • Tencent/Netease: China Game Approval Resumption Is a Relieve, but Not Out of Tunnel
  • Zhihu Secondary: There Is Upside Potential but Be Cautious
  • Conch Venture (586 HK): Improving Risk-Reward Profile
  • Asymchem Laboratories (6821.HK/002821.CH) – Concerns on Future Growth Momentum
  • Morning Views Asia: Honghua Group, Sino-Ocean Service

Greatview (468 HK): A Packing Case Pick

By David Blennerhassett

  • Earlier this year, Jardine Matheson Holdings (JM SP) was understood to be exploring the sale of its 28% stake in Greatview Aseptic Packaging (468 HK).
  • GA Pack announced its full-year results late last month and for the first time since 2012, opted not to pay a final dividend.
  • Shares are down 20% since that non-dividend announcement. That’s convenient.

CNOOC RMB Share Prices at Small Premium (But CNOOC Still Cheap To Peers)

By Travis Lundy

  • CNOOC’s RMB Issue of 2.6bn Shares (about US$5bn with over-allotment) was priced at a 14.2% premium to Friday’s close. Not Great Bob.
  • But 31 March indications of Q1 results, and the promises of an H-share buyback noted in the Annual Results a day earlier are worthwhile noting.
  • CNOOC continues to trail Global Peers in Price and Forward EBIT multiple since the Executive Order 13959 dampened share demand and booted it from global indices. It’s still cheap though.

VNET’s Languishing Shares Draws an Opportunistic $8.00 Bid

By Arun George

  • VNET, formerly known as 21Vianet Group (VNET US), is a leading carrier and cloud-neutral data centre services provider in China. 
  • It has received a non-binding privatisation proposal from The Hina Group and Industrial Bank Co Ltd A (601166 CH) at $8.00 per ADS, a 48.1% premium to the undisturbed price. 
  • The Board has not made any decisions on the offer. Despite the juicy premium, the offer is unattractive in the context of historical multiples and share prices.    

Zhihu HK Secondary – Going Further than Autohome and Weibo, Stock Might Go Further Down as Well

By Sumeet Singh

  • Zhihu plans to raise around US$130m via a dual primary listing in Hong Kong.
  • Unlike all the prior dual primary/secondary listings which have been done via offering either only primary or a mix of primary+secondary shares, Zhihu’s offering will consist of only secondary shares.
  • In this note, we’ll talk about the deal dynamics and structure.

Tencent/Netease: China Game Approval Resumption Is a Relieve, but Not Out of Tunnel

By Ke Yan, CFA, FRM

  • China announced game approval last night, after 8 months of silence.
  • We discussed in our previous note that China would resume game approval.
  • There is no game approved for Tencent and Netease this round but we believe their approval will come in due time.

Zhihu Secondary: There Is Upside Potential but Be Cautious

By Shifara Samsudeen, ACMA, CGMA

  • Zhihu has filed for a dual primary listing on the HKEx through offering of 26m shares (Class A) by existing shareholders at a maximum offer price of HK$51.8 per share.
  • Two ADS represent one Class A ordinary share and shares closed at US$2.56 per ADS, and the maximum offer price implies a 31.5% premium to the last close.
  • Zhihu’s business model seems to work in favour and the company’s shares are extremely cheap at the current multiples. There is upside but we would remain cautious.

Conch Venture (586 HK): Improving Risk-Reward Profile

By Osbert Tang, CFA

  • Following CCEP spin-off and share price decline, China Conch Venture (586 HK) is now at more attractive valuations relative to the stub, on sum-of-the-parts and on PER multiple. 
  • Growth profile should improve in next two years and it has an optimistic expectation of of 76% increase in waste treatment and 79% growth in on-grid electricity for FY22.
  • New business initiatives including anode and cathode materials of lithium iron phosphate and lithium batteries and used lithium batteries treatment may provide potential medium term upside.

Asymchem Laboratories (6821.HK/002821.CH) – Concerns on Future Growth Momentum

By Xinyao (Criss) Wang

  • The three large orders for COVID-19 small molecule drugs are mostly one-off revenues, and after 2022, Asymchem Laboratories (6821 HK)‘s performance could decline from a high base.
  • In essence, Asymchem mainly relies on cost advantage of large-scale capacity to obtain orders.Without core leading technology in frontier of medicine, Asymchem is difficult to enjoy sustainable industry development dividend.
  • Overall, Asymchem’s moat is not strong enough, and the certainty of the Company’s long-term performance growth is also not high. It could be a short-term trade rather than long-term hold.

Morning Views Asia: Honghua Group, Sino-Ocean Service

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma